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Abstract
BACKGROUND: Genomics has growing relevance to palliative care, where testing largely benefits
relatives. Integration of genomics into the care of patients with palliative care needs has not received the
critical attention it requires, and health professionals report a lack of policy guidance to support them to
overcome practice barriers. SUMMARY: To identify policy recommendations related to: (1) integrating
genomics into the care of patients with palliative care needs and their families, and (2) care of the family
unit, we performed a scoping review of palliative care and genomic policies. Two of 78 policies
recommended integrating genomics into palliative care. Six palliative care policies mentioned genomics
in background information but were without relevant recommendations. No genomics policies mentioned
palliative care in the background information. Across all policies, guidance related to “Delivering FamilyCentred Care” was the most frequent recommendation related to care of the family unit, (n=62/78,
79.5%). KEY MESSAGES: We identified a policy gap related to integrating genomics into palliative care.
Without policy guidance, health services are less likely to commit funding towards supporting health
professionals, reducing the personal and clinical benefits of genomics to patients and relatives. Framing
genomic information as family-centred care enables policy makers to communicate the value of
genomics to palliative care that will resonate with genomic and palliative care stakeholders. These
findings increase awareness among policy makers of the benefits of genomic information to patients with
palliative care needs and their families and call for incorporation of appropriate recommendations into
palliative care and genomic policy.
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ABSTRACT
BACKGROUND: Genomics has growing relevance to palliative care, where testing
largely benefits relatives. Integrating genomics into palliative care has not received
the critical attention it requires. Health professionals report a lack of policy guidance
to support them to overcome practice barriers to identify palliative patients who are
eligible for genetic testing, provide genetic counselling and facilitate genetic testing
or DNA storage.
SUMMARY: To identify policy recommendations related to: (1) integrating
genomics into the care of patients with palliative care needs and their families, and
(2) care of the family unit, we performed a scoping review of palliative care and
genomic policies. Two of 78 policies recommended integrating genomics into
palliative care. Six palliative care policies mentioned genomics in background
information but were without relevant recommendations. No genomics policies
mentioned palliative care in the background information. Across all policies,
“Delivering Family-Centred Care” was the most frequent recommendation related to
care of the family unit (n=62/78, 79.5%).
KEY MESSAGES: We identified a policy gap related to integrating genomics into
palliative care. Without policy guidance, health services are less likely to commit
funding towards supporting health professionals. Without funding, delivering the
benefits of genomics to patients and relatives is more difficult for health
professionals. Framing recommendations about genomics as family-centred care
may resonate with genomic and palliative care stakeholders. These findings highlight
an opportunity to improve the policy landscape and access to genomic information
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for patients with palliative care needs. We call for incorporation of appropriate
recommendations into palliative care and genomic policy.
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INTRODUCTION
Genetics and genomics (herein referred to as ‘genomics’) has growing relevance to most areas of
healthcare, including palliative care, as the genetic basis for disease increasingly influences
treatments, risk management, reproductive options and social decisions.[1] The ability of health
professionals to identify palliative patients who may have an inherited pathogenic variant, provide
genetic counselling, facilitate genomic testing (or DNA storage for future testing) and support family
communication has utility for both the individual and family. For the individual, genomic testing may
help them access personalised therapies , while unaffected family members can have predictive
testing to inform future disease risk and screening or risk-reducing options.[2, 3] Additionally,
genomic testing has utility beyond medical decision-making (often termed ‘personal utility’).[4]
Genomic information has the potential to yield psychological benefits for patients with palliative
care needs; providing answers for the cause of an illness, a sense of control, and relief at knowing
family members may be able to avoid the same disease.[5, 6] For the clinical and personal benefits
of palliative-genomic testing to be realised, integrating genomics into the care of people with
palliative care needs must be added to the palliative care agenda.[7]
Genetic and palliative care health professionals have identified a lack of guidance and organisational
support to overcome barriers to integrating genomics into the care of people with palliative care
needs and their families.[8, 9] In the palliative care context, heightened patient and family emotions,
deteriorating patient health and cognition, and variable genomic attitudes and knowledge may
influence a health professional’s decision to initiate a discussion about genomic testing.[10]
Although some palliative care health professionals have concerns about initiating genomic
discussions with patients who have palliative care needs and their families,[11] there is no evidence
of psychological harm resulting from genomic discussions.[12] In fact, addressing existing concerns
that patients with palliative care needs have about their relatives’ future disease risk may yield
positive psychological benefits.[13] In either case, offering genomic testing to a person at end-of-life
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for the benefit of family members highlights the uncertain ethical and legal terrain of palliative care
health professionals’ duty to the family, particularly where there are complex family dynamics.[14]
Furthermore, the absence of support from health services leaves health professionals alone to
manage the complex ethical, legal and social implications of approaching discussions about
genomics with people who are palliative (and their families), particularly as they near end-of-life.[11]
When these barriers prevent patients with palliative care needs from accessing genomic testing
before they die, their DNA and family history knowledge are irretrievably lost, which in turn ,
impacts the quality of information relatives are provided with about future disease risk and
management.[15]
Positive public policy for genomics in palliative care will support health professionals to deliver the
benefits of genomics to patients and families. Implementation science theories (such as Michie and
colleagues’ “Behaviour Change Wheel”) highlight policy as an important influence upon health
professionals’ capability (e.g. having the knowledge to patients eligible for genomic testing),
opportunity (e.g. processes in place to enable DNA storage at end-of-life) and motivation (e.g. belief
they are acting in patients and families’ best interests).[16] Other frameworks demonstrate the
relationship between the macro- (policy environment), meso- (health services and professional
organisations) and micro-level (patient-provider interactions) factors that affect the success of
health intervention implementation.[17] For instance, policy recommendations ideally stimulate
funding to overcome barriers and develop local guidelines to support health professionals integrate
genomics into their practice. For families to benefit from the genomic testing of their dying affected
relative, supportive policy at a government or organisational level is first needed to generate the
flow-on effects to health services and professionals.[18] Governments and professional
organisations are publishing policies that articulate the significance of genomics to routine medical
care, but it is not known whether existing policies acknowledge the benefits of palliative-genomic
testing or address the practical and ethical challenges health professionals face in the palliative care
context.
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To investigate the policy support available for palliative and genetic health professionals, we
performed a scoping review to identify and map current policy recommendations about the
integration of genomics into the care of people with palliative care needs, including
recommendations related to care of the family unit. We sought to answer the following questions:
1. What global policy guidance is available that describes the integration of clinical genetic and
genomic health information into the care of people with palliative needs and their families?
2. What recommendations in palliative care and genetic/genomic policies regarding care of the
family unit are relevant to the integration of clinical genetic and genomic health information
into the care of people with palliative needs and their families?

METHODS
DESIGN
A scoping review, using the methodology described by the Joanna Briggs Institute, was selected to
map and describe global policy recommendations related to genomics in palliative care, rather than
evaluate impact or effectiveness of recommendations.[19] We used the World Health Organization
Innovative Care for Chronic Conditions framework as an initial conceptual framework, which guided
us to explore the ‘macro’ policy environment.[17] Reporting items aligned with the PRISMA-ScR
extension.[20] An a-priori review protocol was published on Open Science Framework
(https://osf.io/5eumn/) and updated in January 2022 when the second review question was added.
The review team (consisting of palliative care and genetic counselling experts with experience in
systematic and scoping reviews) developed the second review question following initial exploration
of the extracted recommendations about care of the family unit. We identified an opportunity to
determine whether recommendations about care of the family unit could reveal common policy
ground between palliative care and genomics.

5

ELIGIBILITY CRITERIA
Eligibility criteria were developed using the Population, Concept and Context framework.[19] For the
purpose of this review, we used the term ‘policy’, but sought to include a range of governance
documents, including ‘frameworks’, ‘strategies’, ‘standards’ or similar. Policies were required to
focus on the provision of palliative care or clinical genetic and genomic services (including genetic
counselling). We did not include clinical practice guidelines for singular conditions as we aimed to
examine the broader policy environment (for example, service development frameworks were
included, while care guidelines for terminal breast cancer were excluded). Eligible policies were
published in English between 2010 – 2022 and authored by national or state (or equivalent)
governments or their agencies, or international, national or state-based professional palliative care,
clinical genetics/genomics or genetic counselling organisations. To retrieve policies from countries
with the infrastructure to integrate genomics into palliative care, we included policies from the top
20 countries ranked by the Economic Intelligence Unit Quality of Death Index, for the quality of their
palliative care provision.[21] The full eligibility criteria is available in the supplementary material.

INFORMATION SOURCES & SEARCH
The search strategy was co-designed with an information scientist (S.S) and peer-reviewed at a
genetic counselling research seminar. The strategy consisted of three approaches: (1) database
search, (2) web-search (3) emailing key informants. The database and web-search strategies are
available in the supplementary material. We repeated the database and web-search twice: once for
palliative care policies and once for genetic and genomic policies. The search was run on the 1st June
2020 and repeated on the 21st February 2022.
1. Database search: Three databases (Medline, EMBASE and CINAHL) were interrogated using
nesting and Boolean operators to combine relevant terms, such as ‘Guideline’ and ‘Health
Policy’ with ‘Genetic Counseling’, ‘Genetic Testing’, or with ‘Palliative Care’. The database
search was supplemented by hand-searching the Canadian Agency for Drugs and

6

Technologies in Health grey literature tool.[22] Database records were exported to, and
deduplicated in EndNote.[23]
2. Web-search: We designed a systematic web-search to retrieve non-commercially published
documents.[24] Using Google, we constructed a single-line search using nesting and Boolean
operators based on the Medline strategy. To reduce the potential bias of geo-locating
algorithms, we used incognito mode and cleared caches and cookies prior to running the
search.[24] Based on the number of retrieved pages identified on a test run, we made a
pragmatic decision to limit the search to the first ten pages of returned results.[25] The
results were captured by copying the web-site name and URL into a Microsoft Excel
spreadsheet so the same results could be screened by more than one reviewer.[26] On
advice from the information scientist, we ran two additional searches with the “type:PDF”
function (one for palliative care and one for genetic/genomic policies), to increase the
sensitivity of the search towards retrieving policy documents.
3. Emails to key informants: To capture any missed policies, we emailed key informants to cite
their local and/or national palliative care or genetics/genomics policy. Palliative care key
informants were identified in the contact list in the Economist Intelligence Unit Quality of
Death Index.[21] Genetic and genomic key informants were identified via the Transnational
Alliance of Genetic Counseling, consultation with experts, authors identified in this review
and targeted, country-specific web searching.[27]
Forward-searching (using Web of Science database) and backward-searching (reviewing reference
lists) was conducted on all policies meeting inclusion criteria.

SELECTION OF SOURCES OF EVIDENCE
S.W. & C.J. piloted the eligibility criteria by independently screening 25 randomly selected policies.
Changes to criteria included specifying that at least 50% of the policy must be relevant to palliative
care or genetic/genomic service provision. S.W. & G.M. then independently screened 20% of the
records at title and abstract, and full text screening using Covidence and Microsoft Excel.[26, 28] For
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records arising from the web-search, title and abstract screening involved reviewing the web-page,
and full text screening involved reviewing the web-site in full. We also followed any potentially
relevant internal or external web-links (snowballing). With biostatistician consultation (K.R), we used
a Prevalence-Adjusted Bias-Adjusted Kappa statistic and achieved substantial inter-rater agreement
(>0.7) before S.W. screened the remainder of the records independently.[29, 30]

DATA ITEMS & CHARTING
We used a modified Joanna Briggs Institute data extraction instrument with pre-determined data
items (see supplementary material). In addition to policy characteristics (e.g., author, year, country),
we extracted verbatim recommendations with their relevant heading and page number. Ten policies
were randomly selected for S.W., G.M. & C.J. to independently pilot the extraction tool. Changes
included adding extraction fields, including organisation’s jurisdiction (e.g. state, national,
international) and population age group (e.g. paediatric, adult, all ages). S.W. independently
extracted recommendations about genetics and genomics from palliative care policies,
recommendations about palliative care from genetic and genomic policies and recommendations
about care of the family unit from both palliative care and genetic and genomic policies. G.M.
reviewed extracted data from 20% of the included policies and verified accuracy.

CRITICAL APPRAISAL
In line with scoping review guidance, we did not perform critical appraisal assessments on individual
policy documents because (a) policies are not primary research articles and (b) to our knowledge, a
validated critical appraisal tool for policy documents does not exist.[25] However, to embed a quality
check into our eligibility criteria, we required policies to be evidence-based and include a description
of the method by which the policy was developed (informed by the AGREE-tool).[31]

MAPPING & SYNTHESIS
To determine what global policy guidance was available for the integration of genomics into the care
of people with palliative needs, policies were grouped by region, policy focus (palliative care or
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clinical genetics and genomics), jurisdiction (state or equivalent, national or international) and
population age group (paediatric, adult or all ages). The presence or absence of recommendations
related to integration of genomics into palliative care was tabulated and narratively summarised.
To determine which recommendations regarding care of the family unit were relevant to the
integration of genomics into the care of people with palliative needs, S.W. and C.V. independently
grouped recommendations about care of the family unit into one of three categories: (a) Relevant to
palliative care only, (b) Relevant to genetics and genomics only, or (c) Relevant to both palliative care
and genetics and genomics. Initial agreement was 67.44%. S.W. and C.V. then collaboratively
assessed and sorted each recommendation into the appropriate category using a broad approach.
For example, we broadly interpreted the recommendation “If services cannot meet the family's
needs, appropriate referrals are made” as referring to any need (e.g. physical, psychological or
social) and could therefore apply to both palliative care and genetic and genomic services. S.W.
further sorted the recommendations relevant to both palliative care and genetics and genomics into
descriptive categories. C.V. reviewed the descriptive categories and provided feedback, including the
suggestion to collapse and rename some of the categories. Once categories were finalised, we
calculated the percentage of each category as a proportion of the total number of policies. Initially, a
granular-level matrix with all recommendations relevant to both palliative care and genetics and
genomics were cross-tabulated with each policy. Individual recommendations were grouped into
categories to demonstrate which policies included recommendations from each category (note: this
did not represent how frequently the category showed up in each policy). We used descriptive
statistics to calculate the presence of each category across all policies, using proportions (n) and
percentage (%) of the total number of policies (N). We additionally stratified by policy focus
(palliative care or genetics and genomics) and region. To visually represent the proportion of each
category across policies (stratified by region), the biostatistician (K.R.) generated a “heat map” using
‘R’ software.[32, 33] A narrative synthesis accompanies the visual results.[34]
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ETHICS
The University of Technology Sydney Research Ethics Office waived the requirement of ethics
approval for this study. However, the reviewers were mindful of contacting key informants as part of
this project. A maximum of three email attempts were made to each person and no direct quotes
are included.

RESULTS
In total, 78 global policies were included (see PRISMA-flow diagram in Fig. 1). The majority were
palliative care policies (n=61, 78.21%) with a country-level focus (n=41, 52.56%) and relevant to all
ages (n=58, 74.36%). Australian policy accounted for one-quarter (n = 20, 25.64%) of the included
policies. Table 1 provides a detailed summary.

INTEGRATION OF GENOMICS INTO PALLIATIVE CARE
Of the 78 policies, only two (2.56%) included recommendations about integrating genomics into
palliative care (Fig. 2).[35, 36]. The first, an international genomics policy, recommended palliative
care involvement when planning care for people with mitochondrial disease.[35] The second, an
English palliative care policy for patients with neurological disease, recommended being aware of
the psychological impact of a positive family history on the patient, including fear of the disorder and
of their children developing the same disease.[36]
Of the 61 palliative care policies, only six (9.84%) mentioned genomics in the background
information, and none of these incorporated genomics into their recommendations.[37-42] The
background information in these six policies illustrated the increased likelihood of a genetic cause in
palliative children and examples of genetic conditions.[37-42] One policy described the impact of
life-limiting, congenital anomalies, including pain, social isolation, stigmatisation and a lack of
resources to provide long-term palliative care.[40] In three of the six policies that mentioned
genomics in the background, genomic information was referred to in policies, or sections of the
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policy, about paediatric palliative care.[37, 40, 42] Excerpts of the background information are in the
supplementary material. None of the genomic policies mentioned palliative care in their background
information.

CARE OF THE FAMILY UNIT
Almost all policies (n=72/78, 92.31%) had recommendations about care of the palliative patient’s
family. We identified 168 unique recommendations, 55 of which were relevant to palliative care
only, five relevant to genetics and genomics only and 108 recommendations relevant to both
palliative care and genetics and genomics. Recommendations relevant to both palliative care and
genetics and genomics were grouped into 11 descriptive categories (Table 2).
The most frequent category overall (n=62/78, 79.5%), including by region (n=10/18, 55.56%) was
“Delivering Family-Centred Care”, although only 29.41% (n=5/17) of genomic policies included this
category compared to 93.44% (n=57/61) of palliative care policies. This category described the
importance of attending to family members’ psychological, social and spiritual needs. The second
most prevalent category overall was “Governance & Policy” (n=53/78, 67.9%), which recommended
care for families be enshrined in policy and enacted by health services. The least mentioned category
overall (n=5/78, 6.4%) and by region (n=4/18, 22.22%) was “Physical & Symptom Care”, which
related to assessing and managing family members’ physical health (Fig. 3)
In addition to “Delivering Family-Centred Care”, genomic policies gave equal attention to “Ethical
Care” (n=5/17, 29.41%) and “Governance & Policy” (n=5/17, 29.41%). “Ethical Care”
recommendations described the ethical obligations health professionals have towards family
members. For example, that discussions surrounding consent for genomic testing must include
implications for family members. As for the palliative care policies, their other focus was upon
recommendations related to “Governance & Policy” (n=48/61, 78.69%) and “Informational Needs”
(n=43/61, 70.49%). “Informational Needs” recommendations described health professionals’ duty to

11

respond to each family’s unique informational needs by assessing family members’ information
requirements and provide information in an accessible way.

DISCUSSION
This global scoping review of policy recommendations complements the evolving dialogue about
patients’,[12, 43] families’[44] and health professionals’[8, 11, 45] experiences and views of the
barriers and facilitators affecting integration of genomics into palliative care by examining the policy
environment. We have identified and mapped recommendations related to the integration of
genomics into the care of people with palliative care needs. A policy gap was evident, with only two
of 78 policies explicitly including recommendations to integrate genomics into the care of patients
with palliative care needs and their families. We also mapped recommendations about care of the
family unit, finding that “Delivering Family-Centred Care” was a key recommendation across both
palliative care and genomic policies.
Implementing genomics into the palliative care setting requires policy action from the meso- (i.e.
health services and professional organisations) and macro-level (i.e. government).[17] Our review
suggests the palliative care profession is falling behind other medical specialties, such as
oncology,[46] neurology,[47] and cardiology,[48] which have published documents highlighting the
importance of genomics to their patient groups. Despite this, translation of genomics into routine
care is slow and there are numerous reasons why health professionals across specialties do not
broach genomics with their patients.[49] If genomics is not addressed by treating specialists,
palliative care becomes the final point to collect DNA from the affected person for the family’s
benefit before the patient dies and the opportunity is lost.[15] Palliative care and genomic
organisations need to communicate this duty to their health professionals, as guiding relatives to
engage in appropriate levels of screening or risk-reduction is a key clinical and economic benefit
offered by genomics.[50, 51] Palliative care and genomic health professionals have called for
organisational support, including initial tertiary genomic education, continuing professional
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development, co-locating palliative care and genetic teams within health services and developing
point-of-care guidelines to identify high-risk patients.[8, 45] Resources and funding are essential to
the success of these strategies but health services are unlikely to commit these without a positive
policy environment.[18] We have demonstrated a need for policy that articulates the importance of
a genomics discussion before the palliative person dies, acknowledges the complexities and
challenges, and delivers potential solutions to support health professionals.
One reason policy guidance may be lacking is that demonstrating the economic value of genomics in
palliative care is challenging. Traditionally, research assessing the economic value of genomics to the
family unit is measured through rates of predictive testing and changes in an individual’s health
behaviour.[3] To generate economic evidence in the palliative care context, researchers must
overcome difficulties related to ethical concerns (e.g. satisfying institutional review boards that their
research will not unduly harm vulnerable people) and logistical hurdles (e.g. patients dying prior to
research participation).[52] To holistically assess the value of genomics to families and fill this
important gap, health economists have suggested enriching economic evaluations with ethical, legal
and social implication (ELSI) research.[53] As genomics continues to revolutionise healthcare, we see
a need for palliative care implementation research to demonstrate the economic value of genomic
testing to families, alongside the clinical, psychological and social benefits.
Our review corroborated the value of family-centred care to palliative care and clinical genetics,
finding that recommendations related to “Delivering Family-Centred Care” were the most prevalent
category of recommendations across both palliative care and genomic policies.[54, 55] These
recommendations illustrate the importance of attending to family members’ psychological, social
and spiritual needs. Elements of family-centred care align with the personal utility of genomic
information, such as satisfying altruistic motivations to protect their relatives from future disease,
reducing the family’s uncertainty of the future, providing a sense of control and making meaning
through findings answers.[13, 56] Leveraging this common ground offers policy makers an avenue to
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frame the benefits of genomics as family-centred care, so relevant recommendations resonate with
both palliative care and clinical genetic and genomic stakeholders.
With accumulating evidence demonstrating the value of genomics in palliative care, it is timely for
palliative care and genomic policy makers to develop policy recommendations about integrating
genomics into palliative care, so the clinical and psychological benefits of genomics can be realised.
We call for a clear policy stance that communicates the important of committing funding and
resources towards supporting health professionals to address genomics with patients who have
palliative care needs and their families.

STRENGTHS & LIMITATIONS
This review addresses a gap in our understanding of how genomics is conceived in the context of
palliative care and is strengthened by adherence to established scoping review guidance. In addition,
the multi-pronged search strategy (in particular, the web-search) identified relevant policies through
commercial and non-commercial publishers, as opposed to relying solely upon academic databases.
However, web-searching methods are described vaguely in scoping review guidelines, meaning we
relied upon other researchers’ published experiences to develop our own procedures. In addition,
we took steps to reduce the web-searching “bubble-effect” (which is the tendency to retrieve web
records within the searcher’s location), but there appeared to be comparatively more web results
from our home country (Australia).[11] Regarding eligibility criteria, our resources limited us to
English-language policies, so we may have missed relevant recommendations from policies in other
languages. Lastly, to maintain feasibility of the review, we focused upon palliative care and genomic
policies; however, there may be related recommendations in policies in adjacent medical fields (such
as oncology or obstetrics/gynaecology).
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CONCLUSION
The dearth of policy recommendations related to the integration of genomics in the care of people
with palliative care needs and their families is an identified gap. Without a clear policy stance, health
services are unlikely to support health professionals to navigate the complexities of integrating
genomics into routine palliative care. Delivering family-centred care was a prevalent existing
recommendation across both palliative and genomic policies. Policy makers urgently need to harness
this common ground to frame the benefits of genomics as family-centred care, to ensure
recommendations resonate with both palliative care and genomic stakeholders. To realise the
potential clinical, psychological, social and economic benefits of genomic medicine in palliative care,
we call upon policy makers to incorporate recommendations about the integration of genomics in
palliative care to communicate the importance of allocating resources and funding to health
services.
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FIGURE LEGENDS
Fig. 1. PRISMA-flow diagram demonstrating the number of retrieved records, inclusion and exclusion
numbers and reasons for exclusion. From 4685 records, 78 policies were included in the final review.
CINAHL: Cumulative Index to Nursing and Allied Health Literature; CADTH: Canadian Agency for
Drugs and Technologies in Health
Fig. 2. Only two of 78 policies included in this review included recommendations about integrating
genomics into the care of people with palliative care needs.
Fig. 3. The degree of shading in this heat map represents the proportion of policies (as a percentage
of the total policies in that region) that included recommendations about care of the family unit.
Policies are grouped by region on the x-axis, and the descriptive categories of recommendations
related to care of the family unit are listed on the y-axis.
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